Discover a new way to find and share stories you'll love… Learn about Reading Desk

Post Profile



Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center, have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.
read more

share

Response rate high for some patients with metastatic melanoma treated with vemurafenib

Academics / General Science : Science Codex (3 years ago)

TAMPA, Fla. (March 16, 2012) – An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) w... Read Post

Vemurafenib Effective For Some Metastatic Melanoma Patients

Health : Medical News Today (3 years ago)

Results from a phase II multi-center clinical trial involving 132 patients with previously treated BRAF V600-mutant metastatic melanoma, indicate that vemurafenib (PLX4032) - an oral BRAF inhibitor - offered a high rate of response ... Read Post

Vemurafenib Extends Survival To 16 Months For Some Patients With Metastatic Melanoma

Health : Medical News Today (3 years ago)

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinic... Read Post


Copyright © 2011 Regator, LLC